What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Sell
20
CGTX Quote, Financials, Valuation and Earnings
Last price:
$0.30
Seasonality move
:
-43.38%
Day range:
$0.27 - $0.31
52-week range:
$0.22 - $2.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.52x
Volume:
1.5M
Avg. volume:
1.5M
1-year change:
-83.78%
Market cap:
$18.6M
Revenue:
--
EPS (TTM):
-$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CGTX
Cognition Therapeutics
|
-- | -$0.12 | -- | -55.56% | $3.25 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CGTX
Cognition Therapeutics
|
$0.30 | $3.25 | $18.6M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.70 | $5.00 | $53M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.58 | $0.85 | $3.4M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.40 | -- | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$3.61 | $1.00 | $2.6M | -- | $0.00 | 0% | 1.16x |
|
TOVX
Theriva Biologics
|
$0.43 | $7.00 | $3.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CGTX
Cognition Therapeutics
|
-- | -4.020 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.250 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.642 | -- | -- |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CGTX
Cognition Therapeutics
|
-- | -$8.7M | -- | -- | -- | -$9.9M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Cognition Therapeutics vs. Competitors
-
Which has Higher Returns CGTX or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Cognition Therapeutics's net margin of -11511.11%. Cognition Therapeutics's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics-- -$0.14 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About CGTX or ATNM?
Cognition Therapeutics has a consensus price target of $3.25, signalling upside risk potential of 983.33%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 194.12%. Given that Cognition Therapeutics has higher upside potential than Actinium Pharmaceuticals, analysts believe Cognition Therapeutics is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics3 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is CGTX or ATNM More Risky?
Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.
-
Which is a Better Dividend Stock CGTX or ATNM?
Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or ATNM?
Cognition Therapeutics quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Cognition Therapeutics's net income of -$8.5M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics-- -- -- -$8.5M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns CGTX or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Cognition Therapeutics's net margin of -49.65%. Cognition Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics-- -$0.14 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About CGTX or NBY?
Cognition Therapeutics has a consensus price target of $3.25, signalling upside risk potential of 983.33%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.24%. Given that Cognition Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cognition Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics3 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is CGTX or NBY More Risky?
Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock CGTX or NBY?
Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or NBY?
Cognition Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cognition Therapeutics's net income of -$8.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics-- -- -- -$8.5M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns CGTX or NNVC?
Nanoviricides has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics-- -$0.14 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About CGTX or NNVC?
Cognition Therapeutics has a consensus price target of $3.25, signalling upside risk potential of 983.33%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 364.29%. Given that Cognition Therapeutics has higher upside potential than Nanoviricides, analysts believe Cognition Therapeutics is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics3 0 0 NNVCNanoviricides0 0 0 -
Is CGTX or NNVC More Risky?
Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.
-
Which is a Better Dividend Stock CGTX or NNVC?
Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or NNVC?
Cognition Therapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Cognition Therapeutics's net income of -$8.5M is lower than Nanoviricides's net income of -$2.2M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics-- -- -- -$8.5M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns CGTX or OGEN?
Oragenics has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics-- -$0.14 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About CGTX or OGEN?
Cognition Therapeutics has a consensus price target of $3.25, signalling upside risk potential of 983.33%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 731.11%. Given that Cognition Therapeutics has higher upside potential than Oragenics, analysts believe Cognition Therapeutics is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics3 0 0 OGENOragenics0 1 0 -
Is CGTX or OGEN More Risky?
Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock CGTX or OGEN?
Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or OGEN?
Cognition Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Cognition Therapeutics's net income of -$8.5M is lower than Oragenics's net income of -$2.2M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 1.16x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics-- -- -- -$8.5M OGENOragenics1.16x -- -- -$2.2M
-
Which has Higher Returns CGTX or TOVX?
Theriva Biologics has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CGTXCognition Therapeutics-- -$0.14 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About CGTX or TOVX?
Cognition Therapeutics has a consensus price target of $3.25, signalling upside risk potential of 983.33%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1519.25%. Given that Theriva Biologics has higher upside potential than Cognition Therapeutics, analysts believe Theriva Biologics is more attractive than Cognition Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings CGTXCognition Therapeutics3 0 0 TOVXTheriva Biologics1 1 0 -
Is CGTX or TOVX More Risky?
Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock CGTX or TOVX?
Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CGTX or TOVX?
Cognition Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Cognition Therapeutics's net income of -$8.5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CGTXCognition Therapeutics-- -- -- -$8.5M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 42x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 50x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
AMBA alert for Jun 25
Ambarella [AMBA] is up 4.36% over the past day.
Buy
65
EXOD alert for Jun 25
Exodus Movement [EXOD] is down 9.63% over the past day.
Buy
78
SMR alert for Jun 25
NuScale Power [SMR] is down 10.59% over the past day.
